HDIM
JAZZ icon

Hanson & Doremus Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Hanson & Doremus Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed – – 500
2021
Q3 		$0 Buy
+3
New +$453 ﹤0.01% 502

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hanson & Doremus Investment Management's JAZZ Position: Q4 2021 in Review

Hanson & Doremus Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 3 shares.

Hanson & Doremus Investment Management first reported a position in JAZZ in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

  • Hanson & Doremus Investment Management reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Hanson & Doremus Investment Management sold 3 Jazz Pharmaceuticals shares in Q4 2021.
  • Hanson & Doremus Investment Management first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Hanson & Doremus Investment Management's Jazz Pharmaceuticals position peaked at $0 in Q3 2021.
  • 454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Hanson & Doremus Investment Management's 13F filing for Q4 2021, filed 20 Jan 2022.